Study of etrasimod for active ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study tests the drug etrasimod in people with active ulcerative colitis (UC). It looks at how well the drug works and its safety. If you have UC that is not well controlled, this trial might help you manage your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have active ulcerative colitis that your doctor thinks could benefit from etrasimod treatment.
- You have had an endoscopy or sigmoidoscopy within the last 12 months showing active disease.
- You are currently taking etrasimod, and it has been no more than 6 months since you started.
- You have not received more than 2 biologic therapies, and no more than 1 biologic with a JAK inhibitor.
- You can understand and complete study procedures and questionnaires.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two oral medicines — etrasimod (a newer drug that works on the immune system) and mesalazine (a standard anti-inflammatory) — in Chinese adults with active ulcerative colitis. It aims to see which is better at controlling symptoms and is safer. If you have mild to moderate active UC, you may join.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This trial tests a new oral medication for people with active ulcerative colitis that hasn't responded well to standard treatments. The goal is to see if the drug reduces inflammation and improves symptoms.
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
This study tests a new way to monitor ulcerative colitis using stool tests and colonoscopy to detect early signs of cancer. It may help doctors manage long-term ulcerative colitis more safely.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.